Drug intelligence / Profile preview

MEDI-578

Development stage: Discontinued
Lead developer: MedImmune
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

MEDI-578 is a human monoclonal antibody that targets nerve growth factor (NGF), neutralizing its function. NGF is a mediator of chronic pain in conditions such as osteoarthritis and other musculoskeletal disorders. By binding to NGF, MEDI-578 inhibits its activity, aiming to reduce pain associated with these conditions. The drug was developed by MedImmune (now part of AstraZeneca) and reached Phase 1 clinical trials for the treatment of painful osteoarthritis of the knee and musculoskeletal pain, but development was discontinued after early-stage studies[1][2][5].

Other names: Anti-NGF monoclonal antibody

Targets

NGF (Nerve growth factor)

Beyond the preview

Go deeper on MEDI-578.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEDI-578.

Explore the full profile